Dicerna Pharmaceuticals Financials

Dicerna Pharmaceuticals Stock Summary

Dicerna Pharmaceuticals competes with Mannatech Incorporated, Maiden Holdings, Inter Parfums, Timken, and Edgewell Personal. Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk AS. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people.

Dicerna Pharmaceuticals Key Financial Ratios

Generally speaking, Dicerna Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Dicerna Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Dicerna Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Dicerna Pharmaceuticals reports annually and quarterly.

Dicerna Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Dicerna Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Dicerna Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dicerna Pharmaceuticals competition to find correlations between indicators driving Dicerna Pharmaceuticals's intrinsic value. More Info.Dicerna Pharmaceuticals is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Dicerna Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dicerna Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dicerna Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.